2023-07-14 11:30:36 ET
Maravai LifeSciences ( NASDAQ: MRVI ) rose 3.4% amid a report that Germany's Merck KGaA ( OTCPK:MKGAF ) is speculated to be one of the companies looking at the vaccine reagent vendor.
Merck ( OTCPK:MKGAF ) is rumored to have shown some interest in Maravai ( MRVI ) after reports it rejected an offer from PE firm Thomas H. Lee, according to a Betaville "uncooked" alert on Friday, which cited people following the matter.
The latest update comes after Betaville said last month that an unidentified strategic buyer is said to be competing with private equity firm Thomas H. Lee for Maravai ( MRVI ).
Reuters reported in May that Maravai ( MRVI ) r ejected the takeover interest from Thomas H Lee. Also in May, Street Insider said that Thomas H. Lee bid $17 a share f or Maravai ( MRVI ).
For further details see:
Maravai LifeSciences gains on report of takeover interest from Germany's Merck